Codiak BioSciences Inc (CDAK)

NASDAQ
20.54
+0.48(+2.39%)
  • Volume:
    67,028
  • Bid/Ask:
    20.46/20.63
  • Day's Range:
    20.50 - 21.00

CDAK Overview

Prev. Close
20.06
Day's Range
20.5-21
Revenue
16.1M
Open
20.24
52 wk Range
7.9-37.85
EPS
-
Volume
67,028
Market Cap
452.12M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
222,055
P/E Ratio
-
Beta
-
1-Year Change
-
Shares Outstanding
22,043,883
Next Earnings Date
Sep 01, 2021
What is your sentiment on Codiak BioSciences Inc?
or
Vote to see community's results!

Codiak BioSciences Inc News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellStrong Buy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

Codiak BioSciences Inc Company Profile

Codiak BioSciences Inc Company Profile

Employees
105

Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12, an exosome therapeutic candidates, for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; exoASO-NLRP3 for multiple sclerosis, neuropathy, and neurodegeneration; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics, Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Read More
  • Sorry, I wouldnt touch this above 3. Ridiculously overpriced.
    0
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.